TLR9 and infection: TLR2 recognizes a wide range of bacterial components and a combination of TLR2/TLR9 agonists has demonstrated a significant protective effect against both Antibody (Ab) lethal and sublethal infections, and also promotes killing or phagocytosis of Ab by lung epithelial cells and macrophages cells (Scharf et al., 2010).